Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Politicians must push economic integration within SADC, Mboweni
2009-08-31

The outgoing Governor of the Reserve Bank, Mr Tito Mboweni (pictured), believes that for economic regional integration to be realized among the Southern African Development Community (SADC) countries, the political leadership of the region should play a pivotal role.

Mr Mboweni delivered the CR Swart Memorial Lecture, the oldest lecture at the University of the Free State, on the topic: “Seeking greater political and economic integration in Southern Africa in challenging and turbulent financial times”.

He said the necessary macro-economic convergence accords must be put in place for regional integration to take place.

These accords, he said, should be supported by prudent fiscal policies, financial balances among SADC countries, and the implementation of policies which will minimize market distortions.

“In the crafting of the macro-economic policies of the region we have to ensure that market certainty is maintained,” he said.

He said as governors of central banks in the region they have agreed that to achieve these objectives they first have to attain a free trade area.

“When the proposals were drafted the idea was that in 2008 we should have achieved a free trade area,” he explained. “Now we are behind in that regard, meaning that a free trade area has been formally and officially declared but the implementation thereof is behind schedule.”

Mr Mboweni said they were supposed to have a SADC-wide customs union in 2010, a SADC common market in 2015 and a monetary union in 2016.

“In order for us to move towards the regional integration agenda it is clear that there has to be a far greater intra-African trade than is the case now,” he said.

“In Southern Africa most of the trade is with South Africa and the other countries do not trade much with or amongst each other.”

He also said because the South African currency is legal tender in countries like Lesotho, Namibia and Swaziland, they have developed a comprehensive set of proposals with these countries to deal with this matter.

“Our proposals basically center on the creation of a common central bank for South Africa, Lesotho, Namibia and Swaziland which, if created, would form a good basis for the establishment of a SADC-wide central bank.”

He said the macro-economic convergence criteria will not help achieve regional integration without the region’s political will.

“There has to be a commitment by the political leadership in Southern Africa to do the basic things that need to be done for the development of the region,” he said.

“That is where the notion of a developmental state must come in in support of these regional integration initiatives. There is no gain in just shouting developmental state if the basic issues supportive of development are not done.”

Mr Mboweni will leave the Reserve Bank in November this year.


Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt.stg@ufs.ac.za  
31 August 2009

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept